Penumbra, Inc. (PEN) on Decifer

Decifer ranks PEN number 165 of 277 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 10% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 17% a year, profits grew 1,169% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• We do not have a clean read on how it is run yet.
• Revenue growing about 17% with profits up 1,169% and steady high margins is impressive, but no clean read on management and no worldview role keep it mid-pack.

The current read

The evidence on PEN lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Penumbra, Inc. operates in medical - devices. That places it inside the Healthcare, Biotech & Devices story.

Read the full PEN research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.